anonymous
Guest
anonymous
Guest
Very valid point. This is the uphill battle we all face.This person has to understand that Eyecare is like the Wild, Wild West….not monitored at all.
yes this product is OURs but Loteprednol is the foundation of it, and there are several Loteprednol options out there:
-Loteprednol Suspension (very old, Generic)
-Loteprednol Ointment
-Loteprednol Gel (Generic)
-Lotemax SM (Brand)
-Inveltys (Brand)
-Alrex (Brand, and low concentration Loteprednol)
-and also Eysuvis
So doctors don’t even care, many of these formulations have the same foundation and others have different formulations (suspensions, gels, ointments, etc)
Therefore cost and coverage ARE factors and doctors WILL get a similar product with similar benefits just writing a covered product.
I hate “investors” who don’t really know the industry—-if they really are an investor and not some home office troll playing stupid.
hey silly investor, why not pressure HQ to just hire Pam back if you know so much!!!!!!
Why would we want her back? I know the current management is terrible, but I could make a list of why that isn't a good idea.